Promoting medical innovation while developing sound social and business policy: a conversation with Thomas G. Roberts. Interview by Barbara J. Culliton

Abstract

The development of "targeted biologics" as cancer therapy has made the field ripe for investment from the private sector and is changing the face of cancer medicine, while also raising important policy concerns about price, profit, and continued innovation. In this interview Barbara Culliton talks with Thomas Roberts, who sees this world from a unique perspective. Roberts, an oncologist, has practiced at the Massachusetts General Hospital and is currently thinking about innovation as a hedge fund manager.